A novel PDE10A inhibitor just showed safety and efficacy in a large Phase 2 trial for acute schizophrenia. đź‘Ź
📌 PDE10A inhibitors represent a non-dopaminergic approach—targeting phosphodiesterase 10A to modulate both D1 and D2 pathways indirectly. This could be a game-changer for patients who don’t respond to or can’t tolerate traditional D2 blockers.
🔍 The trial demonstrated:
âś… Significant reduction in PANSS total scores
âś… Favorable side effect profile (no EPS or prolactin elevation)
âś… Oral formulation, once daily
This reinforces the urgent need to diversify our treatment mechanisms beyond dopamine antagonism. As treatment-resistant schizophrenia remains a major challenge, we’ll take all the innovation we can get.
🧠Stay tuned—PDE10A could join the ranks of TAAR1 agonists and muscarinic agents in reshaping how we treat serious mental illness.